{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:48:11Z","timestamp":1787168891027,"version":"build-2736575974"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Hyperhemolysis syndrome (HHS) is a rare but severe complication of red blood cell transfusion, characterized by the destruction of both the patient\u2019s and donor\u2019s red blood cells. This condition results in post-transfusion hemoglobin levels lower than pre-transfusion levels, often leading to profound anemia, tissue ischemia, and multiorgan failure. HHS predominantly affects individuals with hemoglobinopathies, particularly sickle cell disease. While the pathophysiology remains poorly understood, proposed mechanisms include bystander hemolysis via complement activation, suppression of erythropoiesis, macrophage-mediated RBC destruction. Refractory cases of HHS are managed with Eculizumab and Tocilizumab, targeting the complement pathway and macrophage activation, respectively. This review analyzed 22 reported cases of HHS identified through PubMed, Embase, and Google Scholar. Of these, 11 patients received Eculizumab, 10 received Tocilizumab, and 1 received both. The cohort had an mean age of 29.5\u202fyears, with 36.4% male and 63.6% female. Most patients had underlying hemoglobinopathies. Outcomes showed improvement in 18 patients without major side effects, while 1 patient showed no improvement, and 3 patients passed away. Despite promising results, concurrent use of other immune-modulating agents during treatment complicates attributing the observed efficacy to specific medications alone. Further studies are required to further evaluate the pathophysiology of HHS and assess the safety and effectiveness of these novel therapies.<\/jats:p>","DOI":"10.3389\/fmed.2025.1651895","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:12:10Z","timestamp":1757995930000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The use of Eculizumab and Tocilizumab in the treatment of Hyperhemolysis syndrome, a comprehensive literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Ali","family":"Aqel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Al-Asa\u2019d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salam","family":"Al-kindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaafar","family":"Altouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Al","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Al-Abdulmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4081\/hr.2017.6934","article-title":"A fatal case of immune Hyperhemolysis with bone marrow necrosis in a patient with sickle cell disease","volume":"9","author":"Karafin","year":"2017","journal-title":"Hematol Rep"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/trf.12876","article-title":"\u201cSunny\u201d Dzik, Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab","volume":"55","author":"Gupta","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1111\/trf.13144","article-title":"Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab","volume":"55","author":"Boonyasampant","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1111\/trf.15198","article-title":"Anti-N and anti-do a immunoglobulin\u202fG alloantibody\u2013mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature","volume":"59","author":"Unnikrishnan","year":"2019","journal-title":"Transfusion (Paris)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/03630269.2018.1540353","article-title":"Successful outcome of Hyperhemolysis in sickle cell disease following multiple lines of treatment: the role of complement inhibition","volume":"42","author":"Vlachaki","year":"2018","journal-title":"Hemoglobin"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/trf.15562","article-title":"Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab","volume":"60","author":"Lee","year":"2020","journal-title":"Transfusion (Paris)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e14991","DOI":"10.7759\/cureus.14991","article-title":"Recurrent Hyperhemolysis syndrome in sickle cell disease","volume":"13","author":"Rehman","year":"2021","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1055\/a-2271-8772","article-title":"Spontaneous extradural hematoma in a sickle cell Anemia patient with Hyperinflammation and thrombotic Microangiopathy successfully treated with Eculizumab: a case report and review of the literature","volume":"85","author":"Ita","year":"2024","journal-title":"J Neurol Surg A Cent Eur Neurosurg"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e31061","DOI":"10.1002\/pbc.31061","article-title":"Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: a single-center case series","volume":"71","author":"Lapite","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"A2054","DOI":"10.1016\/j.chest.2023.07.1405","article-title":"Severe hyperhemolysis syndrome in sickle cell anemia","volume":"164","author":"Daly","year":"2023","journal-title":"Chest"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"103712","DOI":"10.1016\/j.transci.2023.103712","article-title":"A case of hyperhemolysis syndrome in sickle cell disease and concomitant COVID-19","volume":"62","author":"Green","year":"2023","journal-title":"Transfus Apher Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e931107","DOI":"10.12659\/AJCR.931107","article-title":"Delayed severe hemolytic transfusion reaction during pregnancy in a woman with \u03b2-thalassemia intermediate: successful outcome after Eculizumab administration","volume":"22","author":"Cannas","year":"2021","journal-title":"American J Case Rep"},{"key":"ref13","first-page":"A3302","author":"Geiszler","year":"2021"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/vox.12429","article-title":"Abstracts","volume":"111","author":"ALKaabi","year":"2016","journal-title":"Vox Sang"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/jha2.779","article-title":"The role of tocilizumab in the treatment of post-transfusion hyperhaemolysis","volume":"4","author":"Desai","year":"2023","journal-title":"EJHaem"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30390","article-title":"Hyperhemolysis syndrome-a rare complication in a patient with sickle disease","volume":"70","author":"Grant","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000524743","article-title":"Successful Management of Severe Hyperhaemolysis with combined Tocilizumab and rituximab in non-transfusion-dependent Thalassaemia: a case report","volume":"50","author":"El Afifi","year":"2023","journal-title":"Transfus Med Hemother"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/trf.16932","article-title":"Hyperhemolysis in a patient with sickle cell disease and recent <scp>SARS-CoV<\/scp> \u22122 infection, with complex auto-and alloantibody work-up, successfully treated with tocilizumab","volume":"62","author":"Fuja","year":"2022","journal-title":"Transfusion (Paris)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/trf.16805","article-title":"Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: the experience so far","volume":"62","author":"Meenan","year":"2022","journal-title":"Transfusion (Paris)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/hematolrep14030032","article-title":"Acute Hyperhemolysis syndrome in a patient with known sickle cell Anemia refractory to steroids and IVIG treated with Tocilizumab and erythropoietin: a case report and review of literature","volume":"14","author":"Menakuru","year":"2022","journal-title":"Hematol Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1111\/bjh.16103","article-title":"Treatment of post-transfusion hyperhaemolysis syndrome in sickle cell disease with the anti-IL6R humanised monoclonal antibody Tocilizumab","volume":"186","author":"Sivapalaratnam","year":"2019","journal-title":"Br J Haematol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"106732","DOI":"10.1016\/j.yebeh.2019.08.007","article-title":"Combination therapy of immunoglobulin, rituximab, and Tocilizumab in treating acute autoimmune encephalitis","volume":"101","author":"Lee","year":"2019","journal-title":"Epilepsy Behav"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"102938","DOI":"10.1016\/j.bcmd.2025.102938","article-title":"Pegcetacoplan for the treatment of warm autoimmune hemolytic anemia: a case report","author":"Gavriilaki","year":"2025","journal-title":"Blood Cells Mol Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1651895\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:12:10Z","timestamp":1757995930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1651895\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":24,"alternative-id":["10.3389\/fmed.2025.1651895"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1651895","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"article-number":"1651895"}}